These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 23144158)

  • 1. TP53 mutations and rituximab-CHOP.
    Gisselbrecht C
    Blood; 2012 Nov; 120(19):3867-9. PubMed ID: 23144158
    [No Abstract]   [Full Text] [Related]  

  • 2. TP53 and outcome in DLBCL: not only the coding region.
    Jardin F; Coiffier B
    Blood; 2013 May; 121(22):4433-4. PubMed ID: 23723442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study.
    Xu-Monette ZY; Wu L; Visco C; Tai YC; Tzankov A; Liu WM; Montes-Moreno S; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Zhao XF; Choi WW; Zhao X; van Krieken JH; Huang Q; Huh J; Ai W; Ponzoni M; Ferreri AJ; Zhou F; Kahl BS; Winter JN; Xu W; Li J; Go RS; Li Y; Piris MA; Møller MB; Miranda RN; Abruzzo LV; Medeiros LJ; Young KH
    Blood; 2012 Nov; 120(19):3986-96. PubMed ID: 22955915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma.
    Stefancikova L; Moulis M; Fabian P; Vasova I; Zedek F; Ravcukova B; Muzik J; Kuglik P; Vranova V; Falkova I; Hrabalkova R; Smardova J
    Int J Oncol; 2011 Dec; 39(6):1413-20. PubMed ID: 21874232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program.
    Xu-Monette ZY; Møller MB; Tzankov A; Montes-Moreno S; Hu W; Manyam GC; Kristensen L; Fan L; Visco C; Dybkaer K; Chiu A; Tam W; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huang Q; Huh J; Ai W; Ponzoni M; Ferreri AJ; Wu L; Zhao X; Bueso-Ramos CE; Wang SA; Go RS; Li Y; Winter JN; Piris MA; Medeiros LJ; Young KH
    Blood; 2013 Oct; 122(15):2630-40. PubMed ID: 23982177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single nucleotide variation in the TP53 3' untranslated region in diffuse large B-cell lymphoma treated with rituximab-CHOP: a report from the International DLBCL Rituximab-CHOP Consortium Program.
    Li Y; Gordon MW; Xu-Monette ZY; Visco C; Tzankov A; Zou D; Qiu L; Montes-Moreno S; Dybkaer K; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huang Q; Ai W; Ponzoni M; Ferreri AJ; Winter JN; Go RS; Piris MA; Møller MB; Wu L; Wang M; Ramos KS; Medeiros LJ; Young KH
    Blood; 2013 May; 121(22):4529-40. PubMed ID: 23515929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD30, another useful predictor of survival in DLBCL?
    Chan WC
    Blood; 2013 Apr; 121(14):2582-3. PubMed ID: 23557969
    [No Abstract]   [Full Text] [Related]  

  • 8. High-risk diffuse large B-cell lymphoma: can we do better than rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone?
    George A; Tam CS; Seymour JF
    Leuk Lymphoma; 2013 Dec; 54(12):2575-6. PubMed ID: 23597141
    [No Abstract]   [Full Text] [Related]  

  • 9. NF-κB p50 activation associated with immune dysregulation confers poorer survival for diffuse large B-cell lymphoma patients with wild-type p53.
    Cai Q; Tu M; Xu-Monette ZY; Sun R; Manyam GC; Xu X; Tzankov A; Hsi ED; Møller MB; Medeiros LJ; Ok CY; Young KH
    Mod Pathol; 2017 Jun; 30(6):854-876. PubMed ID: 28281555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, phase 2 study of R-CHOP plus enzastaurin vs R-CHOP in patients with intermediate- or high-risk diffuse large B-cell lymphoma.
    Hainsworth JD; Arrowsmith ER; McCleod M; Hsi ED; Hamid O; Shi P; Lin BK; Fayad LE
    Leuk Lymphoma; 2016; 57(1):216-8. PubMed ID: 25956042
    [No Abstract]   [Full Text] [Related]  

  • 11. Genetic polymorphism at
    Bashash M; Connors JM; Gascoyne RD; Meissner B; Schuetz JM; Leach S; Slack GW; Berry BR; Hu H; Sehn LH; Brooks-Wilson AR; Spinelli JJ
    Haematologica; 2017 May; 102(5):e199-e202. PubMed ID: 28154089
    [No Abstract]   [Full Text] [Related]  

  • 12. Complete remission of primary cutaneous intravascular large B-cell lymphoma with R-CHOP followed by rituximab monotherapy.
    Pantelaki I; Tigges C; Nußbaum T; Oellig F; Wieland U; Kreuter A
    Dermatol Ther; 2017 Jul; 30(4):. PubMed ID: 28508527
    [No Abstract]   [Full Text] [Related]  

  • 13. Rituximab and bendamustine in patients with CD20+ diffuse large B-cell lymphoma not eligible for cyclophosphamide, doxorubicin, vincristine and prednisone-like chemotherapy.
    Walter E; Schmitt T; Dietrich S; Ho A; Witzens-Harig M
    Leuk Lymphoma; 2012 Nov; 53(11):2290-2. PubMed ID: 22475324
    [No Abstract]   [Full Text] [Related]  

  • 14. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
    Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
    Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical aspects of TP53 gene inactivation in diffuse large B-cell lymphoma.
    Voropaeva EN; Pospelova TI; Voevoda MI; Maksimov VN; Orlov YL; Seregina OB
    BMC Med Genomics; 2019 Mar; 12(Suppl 2):35. PubMed ID: 30871527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting drug resistance to close the gap in diffuse large B-cell lymphoma.
    Rund D
    Leuk Lymphoma; 2014 Sep; 55(9):1966-7. PubMed ID: 24588736
    [No Abstract]   [Full Text] [Related]  

  • 17. Immunochemotherapy is the standard of care in elderly patients with diffuse large B-cell lymphoma.
    Coiffier B; Salles G
    Blood; 2004 Sep; 104(5):1584-5; author reply 1585-6. PubMed ID: 15317734
    [No Abstract]   [Full Text] [Related]  

  • 18. [Diffuse large B-cell lymphoma: standard treatment and research questions].
    Ohmachi K
    Rinsho Ketsueki; 2019; 60(9):1193-1198. PubMed ID: 31597843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. R2-CHOP vs R-CHOP for diffuse large B-cell lymphoma.
    Fowler NH
    Clin Adv Hematol Oncol; 2014 Sep; 12(9):608-10. PubMed ID: 25654483
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical and Biologic Significance of MYC Genetic Mutations in De Novo Diffuse Large B-cell Lymphoma.
    Xu-Monette ZY; Deng Q; Manyam GC; Tzankov A; Li L; Xia Y; Wang XX; Zou D; Visco C; Dybkær K; Li J; Zhang L; Liang H; Montes-Moreno S; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Parsons BM; Møller MB; Wang SA; Miranda RN; Piris MA; Winter JN; Medeiros LJ; Li Y; Young KH
    Clin Cancer Res; 2016 Jul; 22(14):3593-605. PubMed ID: 26927665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.